AbCellera rises 9% after hours as beneficiary of COVID antibody cocktail EUA expansion

Dec. 03, 2021 4:40 PM ETAbCellera Biologics Inc. (ABCL)LLYBy: Jonathan Block, SA News Editor4 Comments

Upward arrow made of dollar banknotes on white background - Concept of growing and upward trend of dollar currency

CalypsoArt/iStock via Getty Images

  • Shares of AbCellera Biologics (NASDAQ:ABCL) are up 9% in post-market trading, apparently getting a boost from the FDA Emergency Use Authorization expansion earlier in the day for bamlanivimab and etesevimab, developed with Eli Lilly

Recommended For You

Comments (4)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.